Equities

ImmuneOnco Biopharmaceuticals Shanghai Inc

ImmuneOnco Biopharmaceuticals Shanghai Inc

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments609635668
Total Receivables, Net0.950.990.03
Total Inventory------
Prepaid expenses779.3120
Other current assets, total0.136.3616
Total current assets687652704
Property, plant & equipment, net159174164
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term261220
Other long term assets1.871.871.66
Total assets875840893
LIABILITIES
Accounts payable166.978.69
Accrued expenses343931
Notes payable/short-term debt6000
Current portion long-term debt/capital leases4.405.605.10
Other current liabilities, total1.740.242,433
Total current liabilities116522,478
Total long term debt109.0213
Total debt751519
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities126612,491
SHAREHOLDERS EQUITY
Common stock3743560
Additional paid-in capital9136546.91
Retained earnings (accumulated deficit)(539)(231)(1605)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.1)----
Total equity748779(1598)
Total liabilities & shareholders' equity875840893
Total common shares outstanding374356356
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.